FRANCIS ARMENDARIZ: Open Payments
NPI 1265442693 · LAWTON, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$823 in 65 payments from 9 companies in 2025. Trend: 2023 $204 · 2024 $715 · 2025 $823
Food & beverage: $823
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 28 | $404 |
| ABBVIE INC. | 25 | $167 |
| Supernus Pharmaceuticals, Inc. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $57 |
| Brainsway USA INC | 1 | $40 |
| Lundbeck LLC | 2 | $36 |
| Sage Therapeutics, LLC | 1 | $22 |
| Averitas Pharma Inc. | 1 | $21 |
| Novo Nordisk Inc | 1 | $16 |
Products named: REXULTI, VRAYLAR, Qelbree, CAPLYTA, Deep TMS SYstem, ZURZUVAE, QUTENZA, Ozempic.
Industry payments across OK — which companies pay providers there.
